AR-V7 as a biomarker for resistance to treatment with abiraterone/enzalutamide in three Latin American countries: a hypothetical cost-saving analysis.

Prostate cancer is the most incident and one of the deadliest male cancers in Latin America. Treatment for patients with metastatic castration-resistant prostate cancer (mCRPC) includes androgen receptor signaling inhibitors (ARSi) such as abiraterone and enzalutamide, for which AR-V7, an androgen receptor splice variant, has emerged as a biomarker for primary resistance.

The induction of AMPK-dependent autophagy leads to P53 degradation and affects cell growth and migration in kidney cancer cells.

The most common subtype of renal cell carcinoma (RCC) is the clear cell RCC (ccRCC) that accounts for 70-80% of cases. The fate of ccRCC is linked to alterations of genes that regulate TP53. The dysfunction of p53 affects several processes including autophagy, which is increased in different advanced carcinomas and could be associated with […]

X